- 中国医学科学院阜外医院
China Oxford Centre for International Health Research (herein after called "the Centre"), based at International Collaborative Centre, National Centre for Cardiovascular Diseases and Fuwai hospital, Chinese Academy of Medical Sciences, is the unique "Innovative Team for Clinical Research in Cardiology" funded by the Ministry of Science and Technology. The Centre mainly focuses on large-scale clinical trials, outcomes research, large-scale population studies, cardiovascular genomics, pharmacogenomics and individualized treatment, health economics and policy, and health big data development and application, aiming to provide reliable evidence for guidelines, and health policy-making, to best allocate medical resources and to promote optimized medical care. Our mission is to improve health and health care through targeted research and bring benefits to all mankind.
Clinical trials: evaluating efficacy and safety for commonly used treatments in China
The Centre has set a precedent in successfully conducting a succession of large-scale, randomized outcomes trials in China, including COMMIT, HPS2-THRIVE, HPS3/TIMI55:REVEAL, ISCHEMIA, and FOURIER. These landmark trials recruited more than 100,000 patients and have profound influences on clinical practice. We obtained first-hand evidences on efficacy and safety for commonly used cardiovascular drugs in China; for the first time in the world, we confirmed that clopidogrel could reduce in-hospital mortality for patients with acute myocardial infarction (AMI). We also found that the incidence of myopathy among patients taking simvastatin was 10 times higher in China than that in western countries. These evidences directly affected the drug regulations in many countries, and the revisions of more than 40 clinical guidelines (domestic and abroad) , benefiting millions of patients around the world. The pre-registration system that the centre created was adopted by many countries including the US and the UK, significantly improving the efficiency and quality of recruitment process for large-scale clinical trials.
Outcomes research: medical quality evaluation and improvement
The Centre has initially created the large-scale, multi-centre evaluation methods for quality of care and was named the national medical quality control Centre of CVD. We are the pioneers in evaluating the quality of treatment for patients with AMI or undergoing percutaneous coronary intervention (PCI) in a nationally representative collaborating network of 31 provinces, and identified targets for improvement for CVD care in China (China PEACE study). The Lancet commented it as "an important step towards improving health care in China, and should be cherished as anopportunity that could translate into saving hundreds of thousands of lives". We then conducted aseries of China PEACE studies with the focus on targeted quality improvement initiatives and patient-level health management evaluation. The evaluation system has been adopted by many domestic institutions, and has been applied in other areas such as stroke and chronic kidney disease, providing reliable evidence for medical quality improvement and healthcare policy-making in China.
Large-scale population studies: disease surveillance andintegrated management
The Centre is the national coordinating base of China PEACE Million Persons Project (MPP), which seeks to explore a practicable, sustainable and lower-cost disease management model, and provide evidence for the Chinese government in primary healthcare reform and policy-making. MPP has set up the database for cardiovascular prevention and control and laid foundation for researches on pathogenesis analysis and new drug development through screening and managing high-risk individuals for CVD across 31 provinces/ municipalities in China. Up to now, 1.4 million has been screened, and 332 thousand high-risk individual shave been under management. By 2020, the project will generate a CVD database and bio-bank for more than 4.8 million Chinese people, and set up the world's largest cohorts for both high-risk individuals for CVD and genetic rare diseases.
Studies on pathogenesis,human genetics and pharmacogenomics
Based on the previous work, the Centre has established a Bio-Bank of 2,500m2 with international standard, collecting and storing over 89 million biological sample, including blood, urine, and myocardial tissue. Big breakthroughs have been made in early identification and treatment for vulnerable plaques, individualized lipid-lowering therapy, as well as detection of gene mutation among patients with familial hypercholesterolemia. The Centre is building a genetics laboratory under cooperation with the world-renowned Amgen-deCODE, aiming to conduct innovative researches on community genomics and pharmacogenomics.
Health economics and health policy research
Funded by the National Development and Reform Commission, the Centre is leading the National Survey on Primary Care in China, which will inform policy and research on primary care in China. A nationwide survey was conducted on service capacity and quality of primary healthcare among 3,400 urban and rural primary care institutions: we collected 10 types of original documents (human resources, financial management, available medicine, etc.), and conducted questionnaire survey among institutional managers, health professionals, and the public. The Commission will help understanding China's primary health system and provide first-hand data for primary care reform. Moreover, the Lancet invited the Centre to lead the Lancet Commission, drafting a report and series of articles on primary care in China, which will provide feasible suggestions for China's primary care service. In addition, with the joint efforts of London School of Economics and Political Science, we established LSE-NCCD Hub for Health Economics and Policy Research, which will serve as one of the key thinktanks promoting China's health reform.
Research on key technology and application of big data
Commissioned by the National Health and Family Planning Commission, the Centre is now building up the National Big Data Centre for CVD, with current volume of various research data up to more than 120 TB. The Centre has already launched a big data platform that meets national A-level standard, which can integrate, archive, and analyze data from different sources suchas medical charts, medical images and genetic information. So far, we have established the data management regulation and standard operating procedures, and are exploring the application of database in aspects of quality evaluation and improvement, commonly-used drug evaluation, diseases and risk factors surveillance, health education and management at grass-root level, pathological mechanisms analysis, and new drug development; and to develop ageneral data model for comprehensive drug evaluation. It is estimated that the Centre will make breakthroughs in medical big data in the future.
Prof. Lixin Jiang, MD, PhD, FACC, FAHA, FESC National Centre for Cardiovascular Diseases (NCCD) - Assistant Director, NCCD - Director, International Collaborative Centre - Co-Director, China Oxford Centre for International Health Research - Co-Director, LSE-NCCD Hub for Health Economics and Policy Research - Director, National Cardiovascular Bio-bank Centre Fuwai Hospital, CAMS & PUMC - Director, Key Laboratory of Clinical Trial Research in Cardiovascular Drugs, NHFPC - Office Director, Drug Clinical Trial Institution - Deputy Director, Centre of Dislipidemia and Cardiovascular Disease (51 Ward) - Doctoral mentor, Chinese Academy of Medical Sciences and Peking Union Medical College - Executive Deputy Director, National Clinical Research Centre Editor-in-Chief, The Lancet Chinese Edition Editor, Atherosclerosis & Hypertension |
As the director of "Innovative Team for Clinical Research in Cardiology", Dr. Jiang leads 7 national research projects funded by Chinese Government, and is principal investigator in China for 11 international multi-centre clinical trials. These studies have involved more than 1,200 hospitals and over 100,000 patients in China, which generated ample first-hand data of Chinese people. The results were incorporated into clinical guidelines in China and internationally. She has led nationally representative landmark studies to determine quality of care across China and developed initiatives and accountability for quality improvement for major chronic diseases, and proposed the idea of building up a learning health care system in The Lancet. She has been leading the China PEACE Million Persons Project, which includes a cohort of millions of high-risk individuals for CVD, and a well-established collaborative network for primary care. The successful implementation of MPP in China, which includes health management, drug and medical device development, technology evaluation, and policy-making, will provide China's solution for health systems all over the world. In 2012, The Lancet published a profile about Dr.Jiang, commenting that she is "at the heart of China's evidence base".
Dr. Jiang leads the efforts to usher in an era of sophisticated national clinical research infrastructure and processes in China, also plays prominent roles in international and national committees e.g., the World Health Organization, Global Alliance for Chronic Diseases, Committee of Experts on Rational Drug Use (NHFPCC), Committee of Experts on Medical Ethics (NHFPC), Collaborative Innovation Strategic Alliance of National Clinical ResearchCentre (MOST). The standardized evaluation system for clinical research that she led and generalized has won four provincial/ministerial awards, for instance, first prize of Beijing Science and Technology Award. In 2016, she was enrolled in China’s national "Ten Thousand Talent Program", selected as the leading talent in technology innovation, and awarded "Women Transforming Leadership Program Award" by the European Society of Cardiology.
Dr. Jiang has published 121 original research papers and reviews, among which 71 publications as first author or corresponding author, with a total citation number of 1,906. She has 4 publications as the first (including co-first) author or corresponding author in The Lancet, 1 in the Journal of the American Medical Association, 1 in European Heart Journal, and 3 and 4 publications as co-author in New England Journal of Medicine and The Lancet, respectively.
III. Application Requirements
●Major: Clinical Medicine, Public Health, Epidemiology and Medical Statistics, Health Economics, Molecular Biology and Genetics, Bioinformatics, Big Data, Pharmacology, or other medical related majors.
●Bachelor degree or above, those with related working experience is preferred.
●Be in good health.
IV. Application Materials
●Application form (including basic personalinformation)
●Resume
●Personal statement (including but not limited to: education experience or working experience, study plan)
●Two recommendation letters
●Photocopy of certificates for academic achievements, such as articles, publications, patents etc.
V. Application Instruction
●The training program has four types of duration: 1 month, 3months, 6 months and 12 months
●Applicants should prepare all the materials listed above and submit to danwei.zhang@fwoxford.org.
●Once approved, the Centre will inform applicants via email.
●The Centre will provide invitation letter. Applicants should apply visa by themselves.
●Tuition for the training program is waived. Travel expense and accommodation costs will be the applicant's responsibility.
●Certificates will be given to those with excellent performance.
VI. Contact
●Website: http://chinaoxford.fuwai.com
●Email: danwei.zhang@fwoxford.org
●Telephone: (0086)10-60866714
Application Form for China Oxford Centre for International Health Reasearch.doc
北京市西城区北礼士路167号
医院总机：010-68314466/88398866
咨询电话：010-88322674
（工作日am：8:00-12:00、pm：13:00-17:00）
24小时投诉电话：
010-88396255（工作日8:00-17:00）
010-88398752（工作日17:00-次日8:00及非工作日）
100037
